According to a research report published in the A year 2014, by scientists of Tata Memorial Hospital, Mumbai, India; ovarian Cancer is the fifth leading cause of total cancer related deaths. The survival rate is only about 5 years in 30-40% of the patients. According to experts, the most common cause is related to delayed diagnosis. Although there are many advanced diagnostic tools that involve biochemical tests, diagnosis using imaging techniques, etc.; detection and diagnosing in the initial symptomatic phase is still a major road block. A sensitive biomarker that is expressed even in early stages is a need and ray of hope for reducing the burden of mortality on ovarian cancer.
